Array ( [0] => Applebot/0.1 [1] => facebookexternalhit/1.1 [2] => LinkedInBot/1.0 [3] => meta-externalagent/1.1 [4] => Amazonbot/0.1 [5] => BLEXBot/1.0 [6] => DotBot/1.2 [7] => Qwantbot/1.0_1997801 [8] => AhrefsBot/7.0 [9] => DataForSeoBot/1.0 [10] => MatchorySearch/1.3 [11] => WRTNBot/1.0 [12] => Sogou web spider/4.0 [13] => MojeekBot/0.11 [14] => Yeti/1.1 [15] => SeznamBot/4.0 [16] => SemrushBot-SI/0.97 [17] => MistralAI-User/1.0 [18] => Qwantbot/1.0 [19] => coccocbot-web/1.0 [20] => coccocbot-image/1.0 [21] => PlagAwareBot/3.2 [22] => Barkrowler/0.9 [23] => AwarioSmartBot/1.0 [24] => PetalBot [25] => archive.org_bot [26] => Iframely/1.3.1 [27] => LogRocket-AssetCacher [28] => Slackbot 1.0 [29] => node-fetch/1.0 [30] => MJ12bot/v1.4.8 [31] => MJ12bot/v2.0.0 [32] => Timpibot/0.9 [33] => AwarioBot/1.0 [34] => MJ12bot/v2.0.1 [35] => Qwantbot/1.0_2850318 [36] => SiteAuditBot/0.97 [37] => Scrapy/2.11.2 [38] => CCBot/2.0 [39] => MJ12bot/v2.0.2 [40] => Scrapy/2.13.3 [41] => WordPress/6.8.3 [42] => MJ12bot/v2.0.4 [43] => SemrushBot/7~bl [44] => Qwairy-Bot/1.0 [45] => Embedly/0.2 [46] => GeedoProductSearch [47] => SemrushBot [48] => vkShare [49] => inkrich [50] => Discordbot/2.0 [51] => IbouBot/1.0 [52] => trafilatura/1.6.3 [53] => AnsehnBot/1.0 [54] => WP-URLDetails/6.8.3 [55] => HubSpot Crawler [56] => ShapBot/0.1.0 [57] => udu/1.6.5 [58] => aiohttp/3.13.1 [59] => l9scan/2.0 [60] => Trident/5.0 [61] => SmartBotCrawler/1.0 [62] => ) The user agent is not in the allowed list.Array ( [0] => pingbot/2.0 [1] => Googlebot/2.1 [2] => ChatGPT-User/1.0 [3] => PerplexityBot/1.0 [4] => OAI-SearchBot/1.0 [5] => GPTBot/1.2 [6] => Perplexity-User/1.0 [7] => YandexBot/3.0 [8] => YandexFavicons/1.0 [9] => AdsBot-Google-Mobile [10] => AdsBot-Google [11] => Gemini-Deep-Research [12] => DuckAssistBot/1.1 [13] => DuckDuckBot/1.1 [14] => GoogleOther [15] => YandexRenderResourcesBot/1.0 [16] => YandexImages/3.0 [17] => DuckAssistBot/1.2 [18] => Baiduspider/2.0 [19] => Baiduspider-render/2.0 [20] => bingbot/2.0 [21] => YandexUserproxy [22] => Pingdom.com_bot_version_1.4_ [23] => GPTBot/1.3 [24] => PingdomPageSpeed/1.0 [25] => YandexMobileBot/3.0 [26] => OAI-SearchBot/1.3 [27] => ClaudeBot/1.0 [28] => OAI-SearchBot/1.3 [29] => ) The user agent is an allowed/known agent.
C-reactive Protein Testing Market Size & Growth Forecast 2026–2035, By Segments (Detection Range, Assay Type, End Use, Disease Area), Regional Demand Trends (North America, Asia Pacific, Europe), Key Country Insights (U.S., Japan, South Korea, Germany, France, Italy), and Competitive Landscape
Market Size and Growth Outlook
Base Year Value (2025)
USD 3.42 Billion
CAGR (2026-2035)
4.3%
Forecast Year Value (2035)
USD 5.21 Billion
Historical Data Period
2022-2025
Largest Region
North America
Forecast Period
2026-2035
C-reactive Protein Testing Market Intelligence Snapshot:
-
Regional Market Dynamics:
- North America held 43.31% of the market in 2025, supported by established laboratory infrastructure, high routine testing volumes, and widespread CRP use across hospitals, laboratories, and physician offices.
- Asia Pacific is projected to grow at a 4.9% CAGR, fueled by expanding diagnostic access, rising hospital and decentralized testing demand, and greater use of cost-effective CRP testing for infection assessment and triage.
-
Segment Momentum:
- hs-CRP held a 60.16% share in 2025 because it supports sensitive measurement of low-grade inflammation for routine risk assessment and ongoing patient monitoring.
- ELISA is the fastest-growing assay type as laboratories increasingly value its flexibility for batch testing and broader analytical applications beyond routine automated workflows.
-
Market Expansion Drivers:
- Rising prevalence of chronic inflammatory and cardiovascular diseases driving CRP demand.
- Expansion of point-of-care CRP testing enabling rapid clinical decision-making.
- Growth of preventive screening programs in primary healthcare systems.
-
Leading Market Participants:
Top companies in the C-reactive protein testing market include F. Hoffmann-La Roche Ltd. (Switzerland), Abbott Laboratories (USA), Siemens Healthineers AG (Germany), Danaher Corporation (USA), Thermo Fisher Scientific Inc. (USA), Quest Diagnostics Incorporated (USA), Laboratory Corporation of America Holdings (USA), HORIBA, Ltd. (Japan), Randox Laboratories Ltd. (United Kingdom), Boditech Med Inc. (South Korea).
Global Market Forecast Snapshot:
-
Market Outlook:
- 2025 Market Size: USD 3.42 Billion
- 2026 Market Size: USD 15.2 billion
- Projected Market Size: USD 5.21 Billion by 2035
- Growth Forecasts: 4.3% CAGR (2026-2035)
-
Regional and Segment Outlook:
- Leading Regional Market: North America
- High-Growth Regional Hub: Asia Pacific
- Core Revenue Segment: hs-CRP (Detection Range) | Immunoturbidimetric Assay (Assay Type) | Hospitals (End Use) | Rheumatoid Arthritis (Disease Area)
- Emerging Opportunity Segment: Conventional CRP (Detection Range) | ELISA (Assay Type) | Laboratories (End Use) | Cardiovascular Diseases (Disease Area)
Market Growth Drivers and Industry Trends
Rising prevalence of chronic inflammatory and cardiovascular diseases driving CRP demandAs the burden of conditions such as rheumatoid disorders, infections with inflammatory complications, and cardiovascular risk profiles rises, clinicians rely more heavily on C-reactive protein testing to support initial assessment, monitor disease activity, and guide treatment adjustments. In the C-reactive protein testing market, this translates into higher routine test volumes from hospitals, diagnostic laboratories, and outpatient practices, especially where CRP is used alongside other biomarkers to distinguish acute flare-ups from longer-term disease progression. Its practical value in tracking systemic inflammation also reinforces repeat testing patterns, which supports market expansion through recurring diagnostic use rather than one-time purchasing behavior.
Expansion of point-of-care CRP testing enabling rapid clinical decision-making
The wider availability of point-of-care platforms is changing how CRP is used in frontline care by moving testing closer to the patient and shortening the time between presentation and clinical action. In the C-reactive protein testing market, this strengthens market development by increasing adoption in primary care clinics, urgent care settings, and emergency departments where physicians need fast inflammatory status data to support triage, antibiotic prescribing, or referral decisions. The shift toward near-patient testing also influences procurement behavior, with providers placing greater value on compact analyzers, easy workflow integration, and rapid-result consumables that fit high-turnover clinical environments.
Growth of preventive screening programs in primary healthcare systems
As primary healthcare systems place greater emphasis on early risk identification and routine monitoring, CRP testing is being incorporated more often into preventive care pathways, particularly for patients with metabolic, cardiovascular, or chronic inflammatory risk factors. This is contributing to market size growth in the C-reactive protein testing market by broadening usage beyond acute diagnostic episodes and into scheduled check-ups, chronic disease management plans, and population-level screening initiatives. The effect is especially meaningful because primary care generates steady testing demand and encourages standardized ordering practices, supporting deeper market penetration through recurring use at the first point of contact in the healthcare system.
| Growth Driver Assessment Framework | |||||
| Growth Driver | Impact On CAGR | Regulatory Influence | Geographic Relevance | Adoption Rate | Impact Timeline |
|---|---|---|---|---|---|
| Rising prevalence of chronic inflammatory and cardiovascular diseases driving CRP demand | 2.00% | High | North America, Europe | High | Near Term |
| Expansion of point-of-care CRP testing enabling rapid clinical decision-making | 1.80% | High | North America, Asia Pacific | High | Near Term |
| Growth of preventive screening programs in primary healthcare systems | 1.70% | High | Europe, Asia Pacific | High | Mid Term |
Unlock insights tailored to your business with our bespoke market research solutions - Click to get your customized report now!
Regional Demand Dynamics
Largest Region
North America
43.31% Market Share in 2025
North America held a 43.31% share of the C-reactive protein testing market in 2025, bolstered by broad clinical use of inflammatory biomarker testing across hospitals, diagnostic laboratories, and physician office settings. The region’s leadership is strengthened by established laboratory infrastructure, high testing volumes tied to routine infection and chronic disease evaluation, and the integration of CRP assessment into everyday care pathways where clinicians need fast, standardized results to guide treatment decisions.
Asia Pacific is projected to expand at a 4.9% CAGR over the forecast period, with growth in the C-reactive protein testing market being impelled by rising diagnostic demand across both hospital-based and decentralized care settings. Adoption is accelerating as healthcare systems increase access to basic and rapid blood testing, particularly where providers need cost-effective tools for infection assessment and patient triage, creating stronger day-to-day utilization across a widening base of clinical facilities.
| Regional Market Attractiveness & Strategic Fit Matrix | |||||
| Parameter | North America | Asia Pacific | Europe | Latin America | MEA |
|---|---|---|---|---|---|
| Innovation Hub | Advanced | Developing | Advanced | Nascent | Nascent |
| Cost-Sensitive Region | Low | Medium | Low | High | Medium |
| Regulatory Environment | Restrictive | Neutral | Restrictive | Neutral | Neutral |
| Demand Drivers | Moderate | Strong | Moderate | Moderate | Moderate |
| Development Stage | Developed | Developing | Developed | Emerging | Emerging |
| Adoption Rate | Low | Low | Low | Low | Low |
| New Entrants / Startups | Moderate | Moderate | Moderate | Sparse | Sparse |
| Macro Indicators | Strong | Strong | Stable | Weak | Weak |
Key Country Insights
The U.S. is expanding the use of C-reactive protein testing across emergency care, primary care, and chronic disease management settings. Healthcare providers are prioritizing rapid diagnostic tools that support timely infection assessment and reduce unnecessary antibiotic prescribing.
Japan is integrating C-reactive protein testing into preventive health programs and routine clinical evaluations. The country's aging population is driving demand for reliable biomarkers that aid in early detection of inflammation-related conditions and ongoing disease management.
South Korea is increasing the adoption of rapid C-reactive protein assays in hospitals and clinics seeking faster diagnostic turnaround. Healthcare providers are focusing on technologies that improve patient triage and support efficient management of infectious diseases.
Germany is emphasizing C-reactive protein testing as part of evidence-based diagnostic pathways for inflammatory and infectious diseases. Laboratories and outpatient providers are adopting standardized testing approaches that improve treatment decisions and patient monitoring.
France is promoting broader use of C-reactive protein testing in primary care to support more targeted prescribing practices. Demand is centered on accessible diagnostic solutions that help physicians distinguish bacterial from viral infections and optimize treatment pathways.
Italy is investing in modern laboratory capabilities that incorporate C-reactive protein testing into routine inflammatory disease assessment. Hospitals are prioritizing efficient testing platforms that can handle growing demand for diagnostic monitoring services.
Segment Leadership and Growth Trends
Within the C-reactive protein testing market, hs-CRP held the strongest position in 2025 with a 60.16% share. Its leadership is maintained through its wider use where more sensitive measurement of low-grade inflammation is needed, making it well suited for routine risk assessment and ongoing patient monitoring. That practical advantage supports steady demand across testing environments that require greater analytical sensitivity without changing established laboratory workflows.
Conventional CRP is the fastest-growing detection range segment in the C-reactive protein testing market because it remains closely aligned with high-volume clinical use where rapid identification of acute inflammatory conditions is the priority. Its growth momentum is reinforced through everyday diagnostic demand in standard care settings, where broad clinical familiarity and fit-for-purpose measurement make it a practical choice relative to more sensitivity-focused alternatives.
Assay Type Segment Analysis: Immunoturbidimetric Assay (Largest Segment) vs ELISA (Fastest-Growing Segment)
In 2025, Immunoturbidimetric Assay accounted for a 51.37% share of the C-reactive protein testing market. This segment maintains its lead because it fits efficiently into routine laboratory operations, especially where consistent throughput, straightforward automation, and compatibility with existing clinical chemistry systems matter most. Its continued use is reinforced by the operational preference for assay formats that support regular testing volumes without adding workflow complexity.
ELISA is emerging as the fastest-growing assay type in the C-reactive protein testing market due to its strong fit in settings that require more flexible batch-based testing and broader assay application beyond standard automated routines. Its momentum relative to other assay formats comes from growing demand in laboratories and research-linked environments where test customization and analytical depth are valued over the speed advantages of routine chemistry-platform methods.
| Report Segmentation | |||
| Segment | Sub-Segment | Largest Segment | Fastest Growing Segment |
|---|---|---|---|
| Detection Range | hs-CRP, Conventional CRP, cCRP | hs-CRP | Conventional CRP |
| Assay Type | Immunoturbidimetric Assay, ELISA, Chemiluminescence Immunoassay, Others | Immunoturbidimetric Assay | ELISA |
| End Use | Clinics, Hospitals, Laboratories, Assisted Living Healthcare Facilities, Home, Others | Hospitals | Laboratories |
| Disease Area | Cardiovascular Diseases, Cancer, Rheumatoid Arthritis, Inflammatory Bowel Disease, Endometriosis, Lupus, Others | Rheumatoid Arthritis | Cardiovascular Diseases |
Read our Research ApproachCompetitive Landscape and Market Positioning
Company Profile
Business Overview Financial Highlights Product Landscape SWOT Analysis Recent Developments Company Heat Map Analysis
1. F. Hoffmann-La Roche Ltd. (Switzerland)
2. Abbott Laboratories (USA)
3. Siemens Healthineers AG (Germany)
4. Danaher Corporation (USA)
5. Thermo Fisher Scientific Inc. (USA)
6. Quest Diagnostics Incorporated (USA)
7. Laboratory Corporation of America Holdings (USA)
8. HORIBA Ltd. (Japan)
9. Randox Laboratories Ltd. (United Kingdom)
10. Boditech Med Inc. (South Korea)
Growing demand for rapid inflammatory biomarker assessment is advancing the C-reactive protein testing market, with manufacturers introducing high-sensitivity assays, point-of-care testing solutions, and automated diagnostic platforms that improve testing efficiency and clinical decision-making.
Industry Development/News
| Company Name | Date | Key Development |
|---|---|---|
| HORIBA | Sep-25 | HORIBA entered a strategic partnership with GeodAIsics to develop an AI-enabled solution for early sepsis detection. The collaboration integrates hematology analyzers, including CRP-capable systems, to identify infection and inflammation patterns, strengthening diagnostic decision support and expanding the clinical utility of CRP-linked hematology platforms in acute care settings. |
| Quest Diagnostics | Aug-25 | Quest Diagnostics completed the acquisition of select clinical testing assets from Fresenius Medical Care’s Spectra Laboratories. The transaction enhances Quest’s chronic disease testing capabilities and expands its clinical diagnostics portfolio, supporting broader service integration across kidney disease and inflammation-related testing segments. |
| Siemens Healthineers | Jul-25 | Siemens Healthineers received the My Green Lab ACT Ecolabel certification for more than 150 immunoassay and clinical chemistry reagents, including its Atellica portfolio. This certification reflects improvements in sustainable reagent manufacturing practices, reinforcing the company’s positioning in environmentally optimized diagnostic production and laboratory workflow solutions. |
| Siemens Healthcare Diagnostics Products GmbH | Nov-23 | Siemens received FDA 510(k) clearance for its CardioPhase high-sensitivity C-reactive protein (hs-CRP) test. The approval enables U.S. commercialization of a quantitative CRP assay for cardiovascular risk assessment, strengthening Siemens’ immunoassay portfolio and expanding clinical utility in inflammation and cardiac risk diagnostics. |
| Qlife Holding AB | Jan-23 | Qlife launched the Egoo CRP capsule in Sweden as a soft introduction to its home testing platform. The product enables non-professional biomarker testing and represents an early step toward broader CE-marked clinical use, expanding access to CRP-based inflammation monitoring in decentralized and home-care settings. |
| LumiraDx | Jan-22 | LumiraDx achieved CE marking for its C-reactive protein (CRP) test, enabling commercialization of a portable microfluidic immunoassay system. The test delivers rapid quantitative results and strengthens the company’s point-of-care diagnostics portfolio, supporting faster inflammation assessment in decentralized healthcare environments. |
Frequently Asked Questions
How large is the C-reactive protein testing market?
In 2026 the market for C-reactive protein testing is worth approximately USD 3.54 billion.
How will the C-reactive protein testing industry grow in terms of size and CAGR by 2035?
C-reactive Protein Testing Market size is estimated to increase from USD 3.42 billion in 2025 to USD 5.21 billion by 2035 supported by a CAGR exceeding 4.3% during 2026-2035.
How is point-of-care testing changing procurement priorities in the C-reactive protein testing market?
Healthcare providers increasingly value compact, rapid-testing platforms that integrate easily into clinical workflows, enabling faster triage and treatment decisions while expanding CRP testing across frontline care settings.
What is driving recurring demand for C-reactive protein testing across healthcare systems?
Greater emphasis on preventive screening and chronic disease monitoring is expanding CRP testing beyond acute diagnosis into routine care pathways, creating consistent testing demand across primary care, hospitals, and diagnostic laboratories.
Why does hs-CRP lead the C-reactive protein testing market?
hs-CRP held a 60.16% share in 2025 because it supports sensitive measurement of low-grade inflammation for routine risk assessment and ongoing patient monitoring.
Which assay type is growing the fastest in the C-reactive protein testing market?
ELISA is the fastest-growing assay type as laboratories increasingly value its flexibility for batch testing and broader analytical applications beyond routine automated workflows.
Why does North America lead the C-reactive protein testing market?
North America held 43.31% of the market in 2025, supported by established laboratory infrastructure, high routine testing volumes, and widespread CRP use across hospitals, laboratories, and physician offices.
What is driving rapid growth in the Asia Pacific C-reactive protein testing market?
Asia Pacific is projected to grow at a 4.9% CAGR, fueled by expanding diagnostic access, rising hospital and decentralized testing demand, and greater use of cost-effective CRP testing for infection assessment and triage.
Who holds a significant market share in the C-reactive protein testing landscape?
Top companies in the C-reactive protein testing market include F. Hoffmann-La Roche Ltd. (Switzerland), Abbott Laboratories (USA), Siemens Healthineers AG (Germany), Danaher Corporation (USA), Thermo Fisher Scientific Inc. (USA), Quest Diagnostics Incorporated (USA), Laboratory Corporation of America Holdings (USA), HORIBA, Ltd. (Japan), Randox Laboratories Ltd. (United Kingdom), Boditech Med Inc. (South Korea).
Our Clients
Why Choose Us
Specialized Expertise: Our team comprises industry experts with a deep understanding of your market segment. We bring specialized knowledge and experience that ensures our research and consulting services are tailored to your unique needs.
Customized Solutions: We understand that every client is different. That's why we offer customized research and consulting solutions designed specifically to address your challenges and capitalize on opportunities within your industry.
Proven Results: With a track record of successful projects and satisfied clients, we have demonstrated our ability to deliver tangible results. Our case studies and testimonials speak to our effectiveness in helping clients achieve their goals.
Cutting-Edge Methodologies: We leverage the latest methodologies and technologies to gather insights and drive informed decision-making. Our innovative approach ensures that you stay ahead of the curve and gain a competitive edge in your market.
Client-Centric Approach: Your satisfaction is our top priority. We prioritize open communication, responsiveness, and transparency to ensure that we not only meet but exceed your expectations at every stage of the engagement.
Continuous Innovation: We are committed to continuous improvement and staying at the forefront of our industry. Through ongoing learning, professional development, and investment in new technologies, we ensure that our services are always evolving to meet your evolving needs.
Value for Money: Our competitive pricing and flexible engagement models ensure that you get maximum value for your investment. We are committed to delivering high-quality results that help you achieve a strong return on your investment.
Select Licence Type
